Richard J. White
Technik-/Wissenschafts-/F&E-Leiter bei Vicuron Pharmaceuticals LLC
Aktive Positionen von Richard J. White
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Vicuron Pharmaceuticals LLC
Vicuron Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Vicuron Pharmaceuticals LLC develops pharmaceutical products. It engages in discovering, developing, manufacturing, and commercializing vital medicine for seriously ill patients. The company offers anidulafungin drug, which prevents cell wall formation and other infectious fungi. It also offers antibiotic for the treatment of complicated skin and soft-tissue infections. The company was founded by Christopher T. Walsh in 1995 and is headquartered in King of Prussia, PA. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.1997 | - |
Indel Therapeutics, Inc.
Indel Therapeutics, Inc. BiotechnologyHealth Technology Indel Therapeutics, Inc. operates as a biopharmaceutical company. It focuses on the discovery, development, and commercialization of antibiotics to address the health crisis caused by antibiotics resistance. The firm’s programs are based on Indel's paradigm-changing antimicrobial drug discovery platform that has opened drug targets for the treatment of bacterial and parasitic infections, and potentially, fungal and viral infections. The company was founded by Malcolm C. Kendall in 2008 and is headquartered in Vancouver, Canada.^ ^ | Direktor/Vorstandsmitglied | 29.04.2011 | - |
Karriereverlauf von Richard J. White
Ehemalige bekannte Positionen von Richard J. White
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
F2G Ltd.
F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | Direktor/Vorstandsmitglied | - | 24.11.2010 |
Vorsitzender | 24.11.2010 | 01.12.2018 | |
BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01.01.1985 | 01.01.1997 |
Bristol-Myers Squibb (China) Pharmaceuticals Co. Ltd. | Corporate Officer/Principal | - | - |
Glaxo Group Research Ltd. | Corporate Officer/Principal | - | - |
Lederle Laboratories
Lederle Laboratories Miscellaneous Commercial ServicesCommercial Services Part of Pfizer Inc., Lederle Laboratories is a company that provides testing services. The company is based in Pearl River, NY. | Corporate Officer/Principal | - | - |
Ausbildung von Richard J. White
University of Oxford | Doctorate Degree |
The University of Manchester | Undergraduate Degree |
Statistik
International
Vereinigte Staaten | 4 |
Vereinigtes Königreich | 4 |
Israel | 2 |
Operativ
Corporate Officer/Principal | 4 |
Director/Board Member | 2 |
Chief Tech/Sci/R&D Officer | 1 |
Sektoral
Health Technology | 5 |
Consumer Services | 3 |
Commercial Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
Private Unternehmen | 6 |
---|---|
Vicuron Pharmaceuticals LLC
Vicuron Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Vicuron Pharmaceuticals LLC develops pharmaceutical products. It engages in discovering, developing, manufacturing, and commercializing vital medicine for seriously ill patients. The company offers anidulafungin drug, which prevents cell wall formation and other infectious fungi. It also offers antibiotic for the treatment of complicated skin and soft-tissue infections. The company was founded by Christopher T. Walsh in 1995 and is headquartered in King of Prussia, PA. | Health Technology |
Lederle Laboratories
Lederle Laboratories Miscellaneous Commercial ServicesCommercial Services Part of Pfizer Inc., Lederle Laboratories is a company that provides testing services. The company is based in Pearl River, NY. | Commercial Services |
Glaxo Group Research Ltd. | |
F2G Ltd.
F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | Health Technology |
Indel Therapeutics, Inc.
Indel Therapeutics, Inc. BiotechnologyHealth Technology Indel Therapeutics, Inc. operates as a biopharmaceutical company. It focuses on the discovery, development, and commercialization of antibiotics to address the health crisis caused by antibiotics resistance. The firm’s programs are based on Indel's paradigm-changing antimicrobial drug discovery platform that has opened drug targets for the treatment of bacterial and parasitic infections, and potentially, fungal and viral infections. The company was founded by Malcolm C. Kendall in 2008 and is headquartered in Vancouver, Canada.^ ^ | Health Technology |
Bristol-Myers Squibb (China) Pharmaceuticals Co. Ltd. |
- Börse
- Insiders
- Richard J. White
- Erfahrung